Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3259045 | 0.89 | — | — | |
| SCHEMBL4201207 | 0.88 | TSHR (0.50) | TSHRUSP2HTT | |
| SCHEMBL20215110 | 0.87 | HSD17B10 (0.46) | TSHRHSD17B10USP2KDM4EHTT | |
| SCHEMBL31544297 | 0.87 | STAT3 (0.32) | TSHRHSD17B10 | |
| SCHEMBL10970630 | 0.86 | USP2 (0.52) | TSHRUSP2HTT | |
| SCHEMBL4454453 | 0.84 | USP2 (0.55) | TSHRUSP2HTT | |
| SCHEMBL11521327 | 0.83 | USP2 (0.39) | TSHRHSD17B10USP2HTT | |
| SCHEMBL2457163 | 0.82 | ALDH1A1 (0.35) | — | |
| SCHEMBL15740389 | 0.81 | TSHR (0.33) | TSHR | |
| SCHEMBL8835123 | 0.81 | HSD17B10 (0.41) | TSHRHSD17B10USP2KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3923908-A1 | NOVEL COMPOSITION | Reckitt Benckiser Health Limited (GB) | 2021-12-22 | — | — | EP | claimed |
| CN-113557009-A | Novel compositions | 雷克特本克斯尔健康有限公司 | 2021-10-26 | — | — | CN | claimed |
| WO-2020165578-A1 | NOVEL COMPOSITION | Reckitt Benckiser Health Limited (GB) | 2020-08-20 | — | — | WO | claimed |
| US-10363316-B2 | Pharmaceutical formulation comprising NSAID and cyclodextrin | RECKITT BENCKISER HEALTHCARE (UK) LIMITED (GB) | 2019-07-30 | — | — | US | claimed |
| CN-103260617-B | Comprise the pharmaceutical preparation of NSAID and cyclodextrin | 雷克特本克斯尔医疗保健国际有限公司 | 2016-08-24 | — | — | CN | claimed |
| EP-2651409-B1 | NOVEL PHARMACEUTICAL FORMULATION COMPRISING NSAID AND CYCLODEXTRIN | RECKITT BENCKISER HEALTHCARE INT LTD (GB) | 2016-08-10 | — | — | EP | claimed |
| US-20160008478-A1 | Pharmaceutical Formulation Comprising NSAID And Cyclodextrin | RECKITT BENCKISER HEALTHCARE INTERNATIONAL LIMITED (GB) | 2016-01-14 | — | — | US | claimed |
| US-9138482-B2 | Pharmaceutical formulation comprising NSAID and cyclodextrin | RECKITT BENCKISER HEALTHCARE INTERNATIONAL LIMITED (GB) | 2015-09-22 | — | — | US | claimed |
| US-20140296342-A1 | Pharmaceutical Formulation Comprising NSAID And Cyclodextrin | RECKITT BENCKISER HEALTHCARE INTERNATIONAL LIMITED (GB) | 2014-10-02 | — | — | US | claimed |
| CN-103260617-A | Novel pharmaceutical formulation comprising NSAID and cyclodextrin | RECKITT BENCKISER HEALTHCARE INT LTD | 2013-08-21 | — | — | CN | claimed |
| US-20240165073-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| WO-2023161452-A1 | SOLID AND ORAL ETOPOSIDE TONIRIBATE COMPOSITIONS | CELLACT PHARMA GMBH (DE) | 2023-08-31 | — | — | WO | disclosed |
| EP-4233837-A1 | SOLID AND ORAL ETOPOSIDE TONIRIBATE COMPOSITIONS | CellAct Pharma GmbH (DE) | 2023-08-30 | — | — | EP | disclosed |
| US-11723893-B2 | Isoflavonoid compositions and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| EP-0127098-B1 | DERIVATIVES OF BETA-AMINO-GAMMA-TRIMETHYLAMMONIO-BUTYRATE, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1989-02-08 | — | — | EP | disclosed |
| US-4767781-A | ANTIDIABETIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-08-30 | — | — | US | disclosed |
| EP-0149197-A2 | Pharmaceutical compositions containing drugs which are sparingly soluble in water or instable and methods for their preparation | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-07-24 | — | — | EP | disclosed |
| EP-0127098-A2 | Derivatives of beta-amino-gamma-trimethylammonio-butyrate, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1984-12-05 | — | — | EP | disclosed |
| US-4259333-A | ANTIBIOTICS, BACTERICIDES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723893-B2 | Isoflavonoid compositions and methods for the treatment of cancer | BAX, CASP3, SI | TSHR 4857/4885HSD17B10 576/4885USP2 3163/4885 |
| US-20240165073-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, SI | TSHR 4857/4885HSD17B10 576/4885USP2 3163/4885 |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | TSHR 4715/4885HSD17B10 954/4885USP2 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.